Anixa Biosciences is a biotechnology company focused on using the body's immune system to diagnose, treat and prevent cancer. The company's subsidiary, Anixa Diagnostics Corporation, develops Cchek?, a platform for non-invasive blood tests for the early detection of cancer. The company's subsidiary, Certainty Therapeutics, Inc., develops immuno-therapy drugs against cancer. The company has focused on the development of a treatment for ovarian cancer. The company is also engaged in limited patent licensing activities in the area of encrypted audio/video conference calling.

Babcock & Wilcox Enterprises is a technology-based provider of steam production from fossil and renewable sources. The company's segments are: Babcock & Wilcox, which focuses on the supply of, and aftermarket services for, steam-generating, environmental, and auxiliary equipment for power generation and other industrial applications; Volund & Other Renewable, which provides steam-generating systems, environmental and auxiliary equipment for the waste-to-energy and biomass power generation industries, and plant operations and maintenance services for its systems and equipment; and SPIG S.p.A. (SPIG), which provides custom-engineered cooling systems, services and aftermarket products.

Designer Brands is a footwear and accessories designer, producer and retailer. The company has three segments: U.S. Retail, which includes stores operated in the U.S. under the DSW Designer Shoe Warehouse banner and its related e-commerce site; Canada Retail, which includes stores operated in Canada under The Shoe Company, Shoe Warehouse, and DSW Designer Shoe Warehouse banners and related e-commerce sites; and Brand Portfolio, which includes sales from wholesale, serving retailers as the design and buying agent for products under private labels, and direct-to-consumer e-commerce sites. The company separates its merchandise into three categories: women's footwear; men's footwear; and accessories and other.

Stellar Biotechnologies is a biotechnology company engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH) protein. KLH can be used as an active pharmaceutical ingredient and combined with a disease-targeting agent to create immunotherapies for the treatment of a variety of diseases. The protein is being utilized in active immunotherapies in clinical development for Alzheimer's disease, metastatic breast cancer, Crohn's disease, systemic lupus erythematous, ovarian cancer and various other cancers and diseases.

Good Times Restaurants operates and franchises Bad Daddy's Burger Bar restaurants (Bad Daddy's) and Good Times Burgers & Frozen Custard (Good Times) restaurants. Bad Daddy's and Good Times are two distinctly different, yet complementary, restaurant concepts. Bad Daddy's operates in the casual dining segment of the restaurant industry. Bad Daddy's operates all of its company-owned restaurants under a table service / full-bar service model. The menu is comprised of burgers, salads, sandwiches, and appetizers. Good Times is a quick service restaurant concept offering hand crafted products. Good Times provides a menu of Angus beef and chicken.

Net 1 UEPS Technologies provides financial technology, products and services. The company has developed and owns most of its payment technologies, and where possible, utilizes this technology to provide financial and services to its customers by including them into the formal financial system. The company's primary payment technology is called the Universal Electronic Payment System (UEPS), and its EMV interoperable derivative, UEPS/EMV, utilizes a form of distributed ledger technology, providing decentralized and biometrically secure smart cards that operate in real-time but both off-line and on-line. The company's financial inclusion products and services are delivered through its UEPS-based core banking system.

Rocket Pharmaceuticals is a clinical-stage, multi-platform biotechnology company focused on the development of gene therapies for rare and devastating pediatric diseases. The company has the following inical-stage ex vivo lentiviral vector programs enrolling patients in the U.S. and European Union for Fanconi Anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells, Leukocyte Adhesion Deficiency-I, a genetic disorder that causes the immune system to malfunction and Pyruvate Kinase Deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.